View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
A new plasma volume expander to treat and prevent serious hypovolemia received FDA approval in December. Voluven, which contains a synthetic starch in a colloidal solution, expands plasma volume when administered I.V.
Clinical trials comparing Voluven with Hespan, another starch-based plasma volume expander, suggest that Voluven is equally safe and effective. Tested in patients ranging in ages from less than 2 to 75, Voluven was found to be as safe as other blood volume expanders in patients undergoing various types of major surgery.
The most commonly reported adverse reactions were nausea and pruritis. Other potential problems include elevated serum amylase, hemodilution, and hypersensitivity reactions. Contraindications to the new drug include dialysis, renal failure with oliguria or anuria not related to hypovolemia, severe hypernatremia or hyperchloremia, fluid overload, intracranial hemorrage, and known hypersensitivity to hydroxyethyl starch.
Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com
BD Safety Beyond Needlestick Prevention Learning Center
Sponsored by BD Medical
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top